Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-α-2b and docetaxel

Cancer Research

Volumn 62, Issue 20, 2002, Pages 5720-5726

  Huang, Samuel F ^a   Kim, Sun Jin ^a   Lee, Anh T ^a   Karashima, Takashi ^a   Bucana, Cora ^a   Kedar, Daniel ^a   Sweeney, Paul ^a   Mian, Badar ^a   Fan, Dominic ^a   Shepherd, David ^a   Fidler, Isaiah J ^a   Dinney, Colin P ^a   Killion, Jerald J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; DOCETAXEL; GELATINASE A; GELATINASE B; PEGINTERFERON ALPHA2B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER TRANSPLANTATION; COMPARTMENT MODEL; CONTROLLED STUDY; CYTOTOXICITY; DOSE CALCULATION; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MALE; METASTASIS INHIBITION; MICROVASCULATURE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CADHERINS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON ALFA-2A; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM METASTASIS; PACLITAXEL; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037108881     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Hertzog, P. J., Hwang, S. Y., and Kola, I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol. Reprod. Dev., 39: 226-232, 1994
2. Gutterman, J. U. Cytokine therapeutics: Lessons from interferon-α. Proc. Natl. Acad. Sci. USA, 91: 1198-1205, 1994
3. Krown, S. E. Interferons in malignancy: Biological products or biological response modifiers? J. Natl. Cancer Inst., 80: 306-309, 1988
4. Thomas. H., and Balkwill, F. R. Effects of interferons and other cytokines on tumors in animals: A review. Pharmacol. Ther., 52: 307-414, 1991
5. Singh, R. K., Bucana, C. D., Llansa, N., Sanchez, R., and Fidler, I. J. Cell density-dependent modulation of basic fibroblast growth factor expression by human interferon-β. Int. J. Oncol., 8: 649-656, 1996
6. Vermeulen, P. B., Diriz, L. Y., Martin, M., Lemmens, J., and Van Oosterom, A. T. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon-α-2b. J. Natl. Cancer Inst., 89: 1316-1317, 1997
7. Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., and Fidler, I. J. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res., 5: 2726-2734, 1999
8. Oliveiera, I. C., Sciavolino, P. J., Lee, T. H., and Vilcek, J., Down-regulation of interleukin-8 expression in human fibroblasts: Unique mechanism of transcriptional inhibition of interferon. Proc. Natl. Acad. Sci. USA, 89: 9049-9053, 1992
9. Singh, R. K., Gutman, M., Llansa, N., and Fidler, I. J. Interferon-β prevents the upregulafion of interleukin-8 expression in human melanoma. J. Interferon Cytokine Res., 16: 577-584, 1996
10. Van Damme, J., and Opdenakker, G. Interaction of interferons with skin reactive cytokines: From interleukin 1 to interleukin-8. J. Investig. Dermatol., 95: 90s-93s, 1990
11. Fabra, A., Nakajima, M., Bucana, C. D., and Fidler, I. J. Modulation of the invasive phenotype of human colon carcinoma cells by fibroblasts from orthotopic or ectopic organs of nude mice. Differentiation (Camb.), 52: 101-110, 1992
12. Gohji, K., Fidler, I. J., Tsan, R., Radinsky, R., von Eschenbach, A. C., Tsuruo, T., and Nakajima, M. Human recombinant interferons β and γ decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int. J. Cancer, 58: 380-384, 1994
13. Bulbul, M. A., Huben, R. P., and Murphy, G. P. Interferon-β treatment of metastatic prostate cancer. J. Surg. Oncol., 33: 231-233, 1986
14. Salmon, P., LeContonnec, J. Y., Galazka, A., Abdul-Ahad, A., and Darragh, A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J. Interferon Cytokine Res., 46: 759-764, 1996
15. Einhom, S., and Grander, D. Why do so many patients fail to respond to interferon therapy? J. Interferon Cytokine Res., 16: 275-281, 1996
16. He, X. H., Shaw, P. C., and Tam, S. C. Reducing the immunogenicity and improving the in vivo activity of tricosthin by site-directed pegylation. Life Sci., 65: 355-368, 1999
17. Glue, P., Fang, J. W. S., Rouzier-Panis, R., Raffanel, C., Sabo, R., Gupta, S. K., Salfi, M., and Jacobs, S. Pegylated interferon-α2b: Pharmacokinetic, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther., 68: 556-567, 2000
18. Heathcote, E. J., Shiffman, M. L., Cooksley, W. G. E., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright T. L., Lin, A., Hoffman, J., and De Pamphilis, J. Pegylated interferon α-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med., 343: 2673-2680, 2000
19. Reddy, R. K., Wright T. L., Pockros, P. J., Shiffman, M. L., Everson, G., Reindollar, R., Fried, M. W., Purdum, P. P., Jensen, D., Smith C., Lee, W. M., Boyer, T. D., Lin, A., Pedder, S., and De Pamphilis. J. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C. Hepatology, 33: 433-438, 2001
20. Greene, G. F., Kitadi, Y., Pettaway, C. A., von Eschenbach, A. C., Bucana, C. D., and Fidler. I. J. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am. J. Pathol., 150: 1571-1582, 1997
21. DiPaola, R. S., Rafi, M. M., Vyas, V., Toppmeyer, D., Rubin, E., Patel, J., Goodin, S., Medina, M., Medina, P., Zamek, R., Zhang, C., White, E., Gupta, E., and Hait, W. N. Phase I clinical and pharmacologic study of 13-cis retinoic acid, interferon-α, and paclitaxel in patient with prostate cancer and other advanced malignancies. J. Clin. Oncol., 17: 2213-2218, 1999
22. Petrylak, D. P., MacArthur, R. B., and O'Conner. J. Phase I trial of docetaxel with estramustine in androgen-dependent prostate cancer. J. Clin. Oncol., 17: 958-967, 1999
23. Gelmon, K. The taxoids: Paclitaxel and docetaxel. Lancet, 344: 1267-1272, 1994
24. Picus, J., and Schultz, M. Docetaxel as monotherapy in the treatment of hormone refractory prostate cancer: Preliminary results. Semin. Oncol., 26: 14-18, 1999
25. Delworth, M. G., Nishioka, K., Pettaway. C., Gutman, M., Killion, J. J., von Eschenbach, A. C., and Fidler, I. J. Systemic administration of 4-amidinoindanon-1-(2′-amidino-hydrazone), a new inhibitor of S-adenosylmethionine decarboxylase, produces cytostasis of human prostate cancer in athymic nude mice. Int. J. Oncol., 6: 293-299, 1995
26. Shi, S. R., Key, M. E., and Kalra, K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem., 39: 741-748, 1991
27. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991
28. Yoneda, J., Kuniyasu, H., Crispens, M. A., Price, J. E., Bucana, C. D., and Fidler, I. J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst., 90: 447-454, 1998
29. Radinsky, R., Bucana, C. D., Ellis, L. M., Sanchez, R., Cleary, K. R., Brigati, D. J., and Fidler, I. J. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res., 53: 937-943, 1993
30. Kitadai, Y., Ellis, L. M., Tucker, S. I., Greene, G. F., Bucana, C. D., Cleary, K. R., Takahashi, Y., Tahara, E., and Fidler, I. J. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am. J. Pathol., 149: 1541-1551, 1996
31. Kuniyasu, H., Ellis, L., Evans, D. B., Abbruzzese, J., Fenoglio, C. J., Bucana, C. D., Cleary, K. R., Tahara, E., and Fidler, I. J. Relative expression of E-cadherin and type IV collagenase genes predict disease outcome in patients with resectable pancreatic carcinoma. Clin. Cancer Res., 5: 25-33, 1999
32. Bruns, C., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R., McConkey, D. J., Evans, D. B., Abbruzzese, J. L., Hicklin, D. J., and Radinsky, R. Epidermal growth factor blockage with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res., 6: 1936-1948, 2000
33. Dinney, C. P. N., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. Inhibition of basic fibroblastic growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res., 58: 808-814, 1998
34. Ozawa, S., Shinohara, H., Kanayama, H., Bruns, C. J., Bucana, C. D., Ellis, L, M., Davis, D. W., and Fidler. I. J. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-α. Neoplasia, 3: 154-164, 2001
35. Ezekowitz, R. A. B., Mulliken, J. B., and Folkman, J. Interferon α-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med., 326: 1456-1463, 1992
36. White, C. W., Sondheimer, H. M., Crouch, E. C., Wilson, H., and Fan, L. L. Treatment of pulmonary hemangiomatosis with recombinant interferon-α-2a. N. Engl. J. Med., 320: 1197-1200, 1989
37. Orchard, P. J., Smith, C. M., Woods, W. G., Day, D. L., Dehner, L. P., and Shapiro, R. Treatment of haemangioendotheliomas with α-interferon. Lancet, 2: 565-567, 1989
38. Ezekowitz, A., Mulliken, J., and Folkman, J. Interferon-α therapy of hemangiomas of infancy. Br. J. Haematol., 79: 67-68, 1991
39. Johns, T. G., Mackay, I. R., Callister, K. A., Hertzog, P. J., Devenish, R. J., and Linnane, A. W. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: Higher efficacy of interferon-β. J. Natl. Cancer Inst., 84: 1185-1190, 1992
40. Rios, A., Mansell, P. W., Newell, G. R., Reuben, J. M., Hersh, E. M., and Gutterman, J. U. Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon. J. Clin. Oncol., 3: 506-512, 1985
41. Real, F. X., Oettgen, H. F., and Krown, S. E. Kaposi's sarcoma and AIDS treatment with high and low doses of recombinant leukocyte A interferon. J. Clin. Oncol., 4: 544-551, 1986
42. Sidky, Y. A., and Borden, E. C. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses. Cancer Res., 47: 5155-5161, 1987
43. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., and Blum, R. H. Interferon α-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol., 14: 7-17, 1996
44. Marshall, M. E., Wolf, M., Crawford, E. D., Thompson I. M., Flanigan, R., Balcerzak, S. P., and Meyers, F. J. Evaluation of low dose α-interferon (Roferon-A) in patients with advanced renal cell carcinoma: A Southwest Oncology Group study. Cancer Biother., 10: 205-209, 1995
45. Logothetis, C. J., Hossan, E., Recondo, G., Sella, A., Ellerhorst, J., Kilbourn, R., Zukiwski, A., and Amato, R. 5-Fluorouracil and interferon-α in chemotherapy refractory bladder carcinoma: An effective regimen. Anticancer Res., 14: 1265-1279, 1994
46. Starr, R., Wilson, T. A., Viney, E. M., Murray, L. J., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Micola, N. A., and Hilton, D. J. A family of cytokine-inducible inhibitors of signaling. Nature (Lond.), 387: 917-921, 1997
47. Nicholson, S. E., and Hilton D. J. The SOCS proteins: A new family of negative regulators of signal transduction. J. Leukocyte Biol., 63: 665-668, 1998
48. Darnell, J. E. STATS and gene regulation. Science (Wash. DC), 277: 1630-1635, 1997
49. Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., and Yoshizaki, K. Structure and function of a new STAT-induced STAT inhibitor. Nature (Lond.), 387: 924-929, 1997
50. Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche. R., and Owczarek, C. M. SOCSI is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell, 98: 597-608, 1999
51. Suzuki, A., Hanada, T., Mitsuyama, K., Yoshida, T., Kamizono, S., Hoshino, T., Kubo, M., Yanashita, A., Okabe, M., Takeda, K., Akira, S., Matsumoto, S., Tononaga, A., Sata, M., and Yoshimura, A. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J. Exp. Med., 193: 471-481, 2001
52. Hong, F., Nguyen, V., and Gao, B. Tumor necrosis factor attenuates interferon signaling in the liver: Involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy. FASEB J., 9: 595-597, 2001
53. Slaton, J. W., Karashima, T., Perrotte, P., Inoue, K., Kim, S. J., Izawa, J., Kedar, D., McConkey, D. J., Millikan, R., Sweeney, P., Yoshikawa, C., Shuin, T., and Dinney, C. P. Treatment with low-dose interferon-α restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin. Cancer Res., 9: 2840-2853, 2001
54. Anzai, H., Kitadai, Y., Bucana, C. D., Sanchez, R., Omoto, R., and Fidler, I. J. Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence. Eur. J. Cancer, 34: 558-565, 1998
55. Herbst, R. S., Yano, S., Kuniyaseu, H., Khuri, F. R., Bucana, C. D., Guo, F., Liu, D., Kemp, B., Lee, J. J., Hong, W. K., and Fidler. I. J. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin. Cancer Res., 6: 790-797, 2000
56. Solorzano, C. C., Baker, C. H., Tsan, R., Traxler, P., Cohen, P., Buchdunger, E., Killion. J. J., and Fidler, I. J. Optimization for the blockage of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin. Cancer Res., 7: 2563-2572, 2001
57. Inoue, K., Slaton, J. W., Davis, D. W., Hicklin, D. J., McConkey, D. J., Karashima, T., Radinsky, R., and Dinney, C. P. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin. Cancer Res., 6: 2635-2643, 2000